Mark your calendars

Article

San Antonio Breast Cancer Symposium to Hold 33rd Annual SymposiumHIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT

San Antonio Breast Cancer Symposium to Hold 33rd Annual Symposium
HIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT



FOREMOST INTERNATIONAL BREAST CANCER SYMPOSIUM HIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT

SAN ANTONIO, TEXAS, DEC. 8-12, 2010




What:
The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year’s symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

To help you plan your coverage of the symposium, the program schedule is available at www.sabcs.org. An electronic press kit containing the press releases and highlighted abstracts will be available to subscribing reporters one week prior to the symposium via EurekAlert and Newswise, and by request through the AACR Communications Department.

This year’s CTRC-AACR San Antonio Breast Cancer Symposium will highlight:
• results of the AZURE trial, which will define the role of zolendronic acid;
• new data on the effect of obesity on risk and patient management;
• how clinicians might move beyond Herceptin in managing HER2 positive breast cancer;
• the role of circulating tumor cells in patient management and risk; and,
• mammography compliance data in the general population.

The CTRC-AACR San Antonio Breast Cancer Symposium attracts world leaders in cancer research and treatment, including clinical oncologists, basic scientists, translational researchers and epidemiologists, working to improve prevention, diagnosis and patient care with the ultimate goal of eradicating breast cancer.

When:
Dec. 8-12, 2010

Where:
Henry B. Gonzales Convention Center
San Antonio, Texas
 

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.